Things are looking up for Johnson & JohnsonJohnson & Johnson beat Wall Street's earnings expectations yesterday and raised its full-year guidance. The company has also been steadily settling opioid lawsuits, with another settlement rumored to be in the works soon. JNJ is rated highly undervalued by S&P Capital IQ, and its post-earnings run looks to be the slow, steady kind rather than a big spike. That's what I like to see. I've picked up a little JNJ and plan to ride it up to at least the 139.50 resistance level. I'm considering a long-term hold, although the political risk makes me cautious about this sector going into an election year.
